Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral finasteride is safe, well tolerated, and effective in improving hair growth in men with androgenetic alopecia, with noticeable benefits seen as early as three months into treatment.

This study found that oral finasteride improved hair growth and reduced hair shedding in male patients with androgenetic alopecia, with no significant side effects observed.

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.

This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.

This article discusses the role of Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants in predicting the response to oral minoxidil for treating female pattern hair loss, without presenting new research findings.

Hair enzyme activity predicts minoxidil success in Brazilian women with hair loss.

This study found that ATR-FTIR spectroscopy combined with machine learning effectively differentiated alopecia areata patients from healthy controls with an AUC of 0.85, and also showed promise in predicting treatment response, particularly through alterations in the Amide I band.

In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

This review explores the complex role of the Innate Immune System in rheumatoid arthritis, highlighting gaps in understanding its functions and interactions with the Adaptive Immune System, offering insights into potential biomarkers and therapeutic strategies for this challenging autoimmune condition.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This study found that adding a SULT1A1 enzyme booster to minoxidil treatment improved hair growth response in 65% of androgenetic alopecia patients who were previous non-responders to minoxidil alone, with females benefiting more than males.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This study discovered that DNA damage independently induces IL-19 and IL-24 cytokines, which regulate senescence-associated secretory phenotype factors, suggesting potential pathways for treating cancer and age-related diseases.

60% of women who didn't respond to 5% minoxidil for hair loss showed significant improvement with a 15% minoxidil solution.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that oral contraceptives effectively suppressed hyperandrogenemia in most patients with hyperandrogenic-insulin-resistant acanthosis nigricans syndrome, though GnRH-a therapy was beneficial for those not responding initially.

This case report describes a patient with Clouston's syndrome and alopecia who responded positively to topical treatment with minoxidil and tretinoin.

This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.

EF and PXE not closely related.

This study found that a diet with purified casein and sulfasuxidine resulted in poor growth and anemia in a pig, which improved after treatment with a liver extract.

In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

This case report describes an adolescent boy with congenital triangular alopecia who showed significant hair regrowth after eight months of treatment with 5% topical minoxidil, achieving full coverage of the affected area without adverse effects.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.